Syndax Pharmaceuticals Reports 82% Year-Over-Year Revenue Growth in Q3 2026
Syndax Pharmaceuticals (SNDX) reported strong third-quarter 2026 financial results, highlighted by an 82% year-over-year increase in total revenue to $83.3 million. This growth was primarily driven by the commercial expansion of Revuforj and Niktimvo. Revuforj saw a 90% year-over-year surge in net revenue, capturing over 80% of the menin inhibitor market share in relapsed/refractory acute leukemia. Despite the robust top-line growth, the company reported a net loss of $49.4 million ($0.55 per share). Management noted that while transplant procedures create temporary revenue headwinds as patients pause therapy, commercial adoption remains high with 620 accounts ordering Revuforj. Additionally, Syndax announced it will cease development of axatilimab for idiopathic pulmonary fibrosis after its Phase 2 trial failed to meet primary endpoints.
Tickers: $SNDX
Topics: biotechnology commercial expansion quarterly earnings revenue growth